Saturday 17 October 2026 Export SIBN’s income statement to Excel — free account

SiBone

SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

19.68 0.23 −1.16%

Follow SIBN

Alert me

Market cap: $892.3M
P/E: 0.0×
Fwd P/E: −34.8×
Dividend yield: —
F-score: 6/9
Altman Z: 7.18
Beneish M: −3.08
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.66

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	10	3	4	5	1	2	5	1	2	8	1	2

Insider Ownership 4.31%

Capital & Financial Ratios $m

Market Cap 892.34

Revenue 213.60

Net Income (14.63)

Free Cash Flow (4.39)

Net Debt (110.31)

Current Ratio 9.15

Debt/Equity 0.20

P/E ratio 0.00

Fwd P/E (34.80)

P/S ratio 4.10

P/B ratio 4.80

Past 5Y EPS Growth —

This Y EPS Growth 9.86%

Next Y EPS Growth 17.43%

Next Y revenue growth 15.52%

Next 5Y EPS Growth 26.24%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.15%

10-year low 10-year high

P/B against its own 10 years 54.23%

10-year low 10-year high

EV/Sales against its own 10 years 34.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	10.00	10.00
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	166	150	148	146
Receivables	22	27	30	31
Inventory	20	27	34	38
Other	—	—	—	—
	211	208	216	220

	2023	2024	2025	Q'26
Payables	5	6	5	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	23	27	25	24

Compound Annual Growth %

	10y	5y	3y
Sales	—	22.32%	23.60%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.95%	21.78%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	53	56	—	—	—
’25	47	49	49	56	201
’24	38	40	40	49	167
’23	33	33	34	39	139
’22	22	26	26	32	106
’21	20	22	22	25	90
’20	17	14	20	22	73

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	1	—	—	—
’25	(5)	0	2	2	(1)
’24	(8)	(6)	0	1	(12)
’23	(11)	(4)	(2)	(2)	(19)
’22	(14)	(15)	(7)	(7)	(42)
’21	(9)	(8)	(9)	(13)	(40)
’20	(9)	(8)	(6)	(8)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(1)	—	—	—
’25	(7)	(2)	(1)	0	(9)
’24	(10)	(9)	(3)	(1)	(23)
’23	(13)	(6)	(3)	(3)	(27)
’22	(16)	(17)	(10)	(8)	(51)
’21	(11)	(10)	(10)	(14)	(46)
’20	(10)	(8)	(6)	(9)	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.10)	(0.09)	—	—	—
’25	(0.15)	(0.14)	(0.11)	(0.04)	(0.44)
’24	(0.27)	(0.22)	(0.16)	(0.11)	(0.75)
’23	(0.32)	(0.30)	(0.25)	(0.27)	(1.13)
’22	(0.52)	(0.54)	(0.41)	(0.32)	(1.79)
’21	(0.37)	(0.42)	(0.48)	(0.43)	(1.71)
’20	(0.47)	(0.44)	(0.33)	(0.28)	(1.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	16.27	14.08	7.20	18.48	11.14	12.44	11.70	12.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	21.96	23.03	32.00	37.21	23.71	29.51	21.64	21.07
People
People	Employees	—	168	183	262	295	352	357	344	349	376
	Revenue/emp, $m	0.00	0.29	0.30	0.26	0.25	0.26	0.30	0.40	0.48	0.53
Income, $m
Income, $m	Revenue	42	48	55	67	73	90	106	139	167	201
	Gross margin, %	87.73	89.35	91.27	89.91	87.87	88.43	85.24	78.78	79.03	79.57
	EBT	(21)	(23)	(17)	(38)	(44)	(57)	(61)	(43)	(31)	(19)
	EBT margin, %	(48.90)	(48.01)	(31.51)	(57.06)	(59.54)	(62.75)	(57.57)	(31.20)	(18.49)	(9.41)
	Net income	(21)	(23)	(17)	(38)	(44)	(57)	(61)	(43)	(31)	(19)
	Depreciation	1	1	1	1	2	4	4	2	(1)	3
Per share, $
Per share, $	Revenue	12.70	13.84	6.97	2.72	2.53	2.72	3.11	3.61	4.03	4.68
	Earnings	(6.21)	(6.65)	(2.20)	(1.55)	(1.50)	(1.71)	(1.79)	(1.13)	(0.75)	(0.44)
	Cash flow	(5.06)	(5.06)	(1.83)	(1.28)	(1.06)	(1.19)	(1.22)	(0.49)	(0.30)	(0.02)
	Capex	(0.13)	(0.14)	(0.12)	(0.10)	(0.09)	(0.19)	(0.28)	(0.20)	(0.25)	(0.20)
	Free cash flow	(5.19)	(5.19)	(1.94)	(1.38)	(1.14)	(1.39)	(1.50)	(0.69)	(0.55)	(0.21)
	Book value	(32.81)	(37.32)	11.34	2.55	5.83	4.06	2.87	4.41	4.03	4.13
	Shares, m	3	3	8	25	29	33	34	38	41	43
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.45	1.45	3.00	7.89	11.84	8.17	4.28	5.77	3.48	4.22
	P/B	0.00	0.00	1.84	8.43	5.13	5.48	4.63	4.73	3.48	4.77
	EV/Sales	2.09	2.09	1.64	7.11	9.82	6.94	3.71	4.84	2.80	3.66
	EV/FCF	(8.20)	(8.20)	(5.89)	(14.05)	(21.69)	(13.62)	(7.72)	(25.36)	(20.43)	(81.02)
Cash, $m
Cash, $m	Operating cash flow	(17)	(18)	(15)	(32)	(31)	(40)	(42)	(19)	(12)	(1)
	Capex	0	0	(1)	(2)	(3)	(6)	(10)	(8)	(10)	(8)
	Free cash flow	(17)	(18)	(15)	(34)	(33)	(46)	(51)	(27)	(23)	(9)
Balance, $m
Balance, $m	Working capital	23	26	127	93	205	159	116	188	181	191
	Total debt	29	39	39	39	39	35	35	36	35	36
	Net debt	1	16	(83)	(53)	(157)	(112)	(62)	(130)	(115)	(112)
	Shareholders’ equity	(109)	(129)	90	63	169	134	98	169	167	178
Returns, %
Returns, %	ROA	(54.71)	(61.22)	(20.02)	(30.06)	(25.69)	(27.35)	(35.20)	(22.34)	(13.42)	(8.06)
	ROIC	0.00	0.00	(107.88)	(215.31)	(194.61)	(144.08)	(102.96)	(74.41)	(42.06)	(21.38)
	ROE	17.29	19.35	89.08	(50.13)	(37.61)	(37.25)	(52.64)	(32.38)	(18.38)	(10.97)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)	Compare
BBNX Beta Bionics, Inc.	$933.8M	— (loss-making)	— (loss-making)	+37.76% (above 0%: growing)	n/m	−1.87% (below 0%: shrinking)	59.04%	(79.90%)	Compare
SIBN SiBone	$892.3M	— (loss-making)	— (loss-making)	+15.18% (above 0%: growing)	n/m	+60.12% (above 0%: growing)	79.54%	(8.58%)
AHCO AdaptHealth Corp.	$871.2M	— (loss-making)	13.2×	+12.66% (above 0%: growing)	n/m	−128.56% (below 0%: shrinking)	14.08%	(18.61%)	Compare
INMD InMode Ltd.	$824.0M	11.3×	11.8×	−0.01% (below 0%: shrinking)	−30.95% (below 0%: shrinking)	−12.63% (below 0%: shrinking)	74.82%	12.82%	Compare
VREX VAREX IMAGING	$784.3M	34.7×	43.4×	+3.69% (above 0%: growing)	n/m	+757.14% (above 0%: growing)	36.44%	10.83%	Compare
Median of peers	$943.8M	—	14.2×	+5.76%	—	−7.25%	47.87%	0.58%

All 149 Medical Devices stocks →

SiBone (SIBN) key facts

Concern: SiBone reported a net loss of $18.9 million, or a loss of $0.44 per share, for fiscal 2025.
Strength: SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024.
SiBone (SIBN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SIBN traded at $19.68, a market capitalization of $892.3 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.1× sales.
Return on equity was −11.0% and debt-to-equity 0.20.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.18 (safe zone) for fiscal 2025.